Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Samsung BioLogics Plans $2.7 Billion IPO in South Korea

publication date: Aug 9, 2016
On Thursday of this week, Samsung BioLogics is expected to file for an IPO on South Korea's main board that will raise between $1.8 and $2.7 billion, valuing the company at $9 billion. Samsung BioLogics, the biopharma subsidiary of electronics conglomerate Samsung, aims to become the world's largest biologic drug CMO. It is also developing its own biosimilar drugs. According to IMS, the global market for biologic drugs will be over $390 billion by 2020 -- representing nearly one out of every three dollars spent for drugs -- which explains why so many pharmas are investing in biologic/biosimilar infrastructure. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital